Chinese experts consensus on the prevention and treatment of complications caused by intraperitoneal perfusion chemotherapy for gastrointestinal tumors (2022 edition).
10.3760/cma.j.cn441530-20220928-00396
- Collective Name:Member of Complication Management Committee of Colorectal Cancer Professional Committee of Chinese Medical Doctor Association;Professional Committee of Colorectal Cancer of China Anti Cancer Association
- Publication Type:Journal Article
- MeSH:
Humans;
Peritoneal Neoplasms/secondary*;
Hyperthermia, Induced;
Consensus;
Quality of Life;
Combined Modality Therapy;
Gastrointestinal Neoplasms/therapy*;
Perfusion;
Colorectal Neoplasms/surgery*;
China
- From:
Chinese Journal of Gastrointestinal Surgery
2022;25(11):947-954
- CountryChina
- Language:Chinese
-
Abstract:
Peritoneal metastasis is one of the common metastasis of gastrointestinal malignancy. Intraperitoneal chemotherapy (including hyperthermic intraperitoneal chemotherapy and intraoperative intraperitoneal chemotherapy) not only can effectively increase the peritoneal drug concentration, but also can reduce side effects of systemic chemotherapy. It can significantly prolong the long term survival of patients with peritoneal metastasis and improve the quality of life. In order to standardize the popularization and application of intraperitoneal chemotherapy, relevant professional committees have formulated expert consensus on intraperitoneal chemotherapy. However, there is no systematic guidance on the prevention and treatment of related complications of intraperitoneal chemotherapy. Under the guidance of the Complications Management Committee of the Colorectal Cancer Professional Committee of the Chinese Medical Association and the Colorectal Cancer Professional Committee of the Chinese Anti-cancer Association, we organized domestic experts in relevant fields to formulate this consensus according to the procedural specifications and relevant literature reports. This consensus aims to summarize the causes of common complications of intraperitoneal chemotherapy such as pneumonia, intraperitoneal hemorrhage, fever, peritonitis, ileus, intestinal dysfunction, anastomotic bleeding, anastomotic leakage, leakage or infection of perfusion tube, nausea and vomiting, myelosuppression, hepatic or nephritic dysfunction. After repeatedly soliciting the opinions of domestic authoritative experts and their discussion and modification, a consensus was formed to provide effective reference for the prevention and treatment of complications.
